Brain-computer interface relieves chronic chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial.

BACKGROUND Chemotherapy-induced peripheral neuropathy (CIPN) includes negative sensations that remain a major chronic problem for cancer survivors. Previous research demonstrated that neurofeedback (a closed-loop brain-computer interface [BCI]) was effective at treating CIPN versus a waitlist control (WLC). The authors' a priori hypothesis was that BCI would be superior to placebo feedback (placebo control [PLC]) and to WLC in alleviating CIPN and that changes in brain activity would predict symptom report. METHODS Randomization to one of three conditions occurred between November 2014 and November 2018. Breast cancer survivors no longer in treatment were assessed at baseline, at the end of 20 treatment sessions, and 1 month later. Auditory and visual rewards were given over 20 sessions based on each patient's ability to modify their own electroencephalographic signals. The Pain Quality Assessment Scale (PQAS) at the end of treatment was the primary outcome, and changes in electroencephalographic signals and 1-month data also were examined. RESULTS The BCI and PLC groups reported significant symptom reduction. The BCI group demonstrated larger effect size differences from the WLC group than the PLC group (mean change score: BCI vs. WLC, -2.60 vs. 0.38; 95% confidence interval, -3.67, -1.46 [p = .000; effect size, 1.07]; PLC, -2.26; 95% confidence interval, -3.33, -1.19 [p = .001 vs. WLC; effect size, 0.9]). At 1 month, symptoms continued to improve only for the BCI group. Targeted brain changes at the end of treatment predicted symptoms at 1 month for the BCI group only. CONCLUSIONS BCI is a promising treatment for CIPN and may have a longer lasting effect than placebo (nonspecific BCI), which is an important consideration for long-term symptom relief. Although scientifically interesting, the ability to separate real from placebo treatment may not be as important as understanding the placebo effects differently from effects of the intervention. PLAIN LANGUAGE SUMMARY Chemotherapy-induced nerve pain (neuropathy) can be disabling for cancer survivors; however, the way symptoms are felt depends on how the brain interprets the signals from nerves in the body. We determined that the perception of neuropathy can be changed by working directly with the brain. Survivors in our trial played 20 sessions of a type of video game that was designed to change the way the brain processed sensation and movement. In this, our second trial, we again observed significant improvement in symptoms that lasted after the treatment was complete.

[1]  A. Rice,et al.  Neuromodulation: more than a placebo effect? , 2019, Pain.

[2]  W. Jonas,et al.  Are Invasive Procedures Effective for Chronic Pain? A Systematic Review , 2018, Pain medicine.

[3]  L. Ramondetta,et al.  The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial. , 2018, Journal of pain and symptom management.

[4]  J. McQuade,et al.  Randomized controlled trial of neurofeedback on chemotherapy‐induced peripheral neuropathy: A pilot study , 2017, Cancer.

[5]  V. Napadow,et al.  Rewiring the primary somatosensory cortex in carpal tunnel syndrome with acupuncture , 2017, Deutsche Zeitschrift für Akupunktur.

[6]  S. Linton,et al.  The role of pain catastrophizing as a mediator in the work disability process following acute low back pain , 2017 .

[7]  Thomas J. Smith,et al.  New Practical Approaches to Chemotherapy-Induced Neuropathic Pain: Prevention, Assessment, and Treatment. , 2016, Oncology.

[8]  T. Kaptchuk,et al.  Placebo Effects in Medicine. , 2015, The New England journal of medicine.

[9]  G. Rücker,et al.  Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis. , 2013, JAMA internal medicine.

[10]  C. Shapiro,et al.  Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. , 2013, JAMA.

[11]  G. Steineck,et al.  Acupuncture compared with placebo acupuncture in radiotherapy-induced nausea--a randomized controlled study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  R. Thatcher,et al.  Diffusion spectral imaging modules correlate with EEG LORETA neuroimaging modules , 2012, Human brain mapping.

[13]  A. Muriel,et al.  The Correlation Between Pain, Catastrophizing, and Disability in Subacute and Chronic Low Back Pain: A Study in the Routine Clinical Practice of the Spanish National Health Service , 2011, Spine.

[14]  D. Drossman,et al.  Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome , 2008, BMJ : British Medical Journal.

[15]  J. Middleton,et al.  Electroencephalographic slowing and reduced reactivity in neuropathic pain following spinal cord injury , 2008, Spinal Cord.

[16]  F. Benedetti,et al.  How prior experience shapes placebo analgesia , 2006, Pain.

[17]  Johannes Sarnthein,et al.  Persistent EEG overactivation in the cortical pain matrix of neurogenic pain patients , 2006, NeuroImage.

[18]  M. Congedo,et al.  Low-resolution electromagnetic tomography neurofeedback , 2004, IEEE Transactions on Neural Systems and Rehabilitation Engineering.

[19]  Robert Schmitt,et al.  Integration of fMRI and simultaneous EEG: towards a comprehensive understanding of localization and time-course of brain activity in target detection , 2004, NeuroImage.

[20]  Edward E. Smith,et al.  Placebo-Induced Changes in fMRI in the Anticipation and Experience of Pain , 2004, Science.

[21]  J. Sarnthein,et al.  Increased EEG power and slowed dominant frequency in patients with neurogenic pain. , 2006, Brain : a journal of neurology.